DICE Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2020 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
DICE Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2020 to Q2 2023.
  • DICE Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2023 was $5.5M, a 30.8% increase year-over-year.
  • DICE Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2023 was $4.39M, a 16.9% decline year-over-year.
  • DICE Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $12.8K, a 130% increase from 2021.
  • DICE Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $5.58K, a 99% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $4.39M $5.5M +$1.3M +30.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $3.09M $4.89M +$3.08M +170% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $12.8K -$9.47M -$5.57M -143% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-15
Q3 2022 $5.59M $3.47M +$307K +9.72% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-09
Q2 2022 $5.28M $4.21M +$3.81M +963% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $1.47M $1.81M +$1.46M +421% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $5.58K -$3.9M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 $3.16M +$3.16M +2119363% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $396K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $347K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q3 2020 $149* Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.